9-ethyl-2-(1H-imidazol-1-yl)-3-nitroimidazo[1,2-a]pyrido[3,2-e]pyrazin-6(5H)-one

ID: ALA5192550

PubChem CID: 168284936

Max Phase: Preclinical

Molecular Formula: C14H11N7O3

Molecular Weight: 325.29

Names and Identifiers

Canonical SMILES:  CCc1cnc2c(=O)[nH]c3cc([N+](=O)[O-])c(-n4ccnc4)nc3n12

Standard InChI:  InChI=1S/C14H11N7O3/c1-2-8-6-16-13-14(22)17-9-5-10(21(23)24)12(18-11(9)20(8)13)19-4-3-15-7-19/h3-7H,2H2,1H3,(H,17,22)

Standard InChI Key:  SHDXFFZFHNPBJX-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 24 27  0  0  0  0  0  0  0  0999 V2000
   -0.7752    0.3309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0606    0.7432    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6513    0.3313    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6513   -0.4938    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0588   -0.9055    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7752   -0.4974    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3658    0.7439    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0804    0.3312    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0804   -0.4938    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3658   -0.9064    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.7952   -0.9064    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4898    0.7435    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4898   -0.9101    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2044   -0.4974    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4898   -1.7353    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2432    0.4079    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7952    1.0209    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3828    1.7353    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5759    1.5637    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6937    0.8833    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.5375    1.5510    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3581    1.6372    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9855    2.1641    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1785    1.9927    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  1  6  1  0
  6  5  2  0
  3  7  1  0
  8  7  1  0
  9  8  1  0
 10  9  1  0
  4 10  1  0
  9 11  2  0
  1 12  1  0
 13  6  1  0
 13 14  1  0
 13 15  2  0
 16 12  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 12  1  0
  8 20  2  0
  7 21  1  0
 21 22  2  0
 22 20  1  0
 21 23  1  0
 23 24  1  0
M  CHG  2  13   1  14  -1
M  END

Alternative Forms

1. Parent:

   

   ALA5192550

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 325.29

Molecular Weight (Monoisotopic): 325.0923

AlogP: 1.23

#Rotatable Bonds: 3

Polar Surface Area: 124.01

Molecular Species: NEUTRAL

HBA: 8

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 10

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 13.78

CX Basic pKa: 5.73

CX LogP: 1.63

CX LogD: 1.62

Aromatic Rings: 4

Heavy Atoms: 24

QED Weighted: 0.45

Np Likeness Score: -1.61

References

1. Jiang X, Wu K, Bai R, Zhang P, Zhang Y..  (2022)  Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.,  229  [PMID:34998058] [10.1016/j.ejmech.2021.114085]

Source

Source(1):

• Scientific Literature